P. Fournel, R. G. Thomas, and P. , Randomized Phase III Trial of Sequential Chemoradiotherapy Compared With Concurrent Chemoradiotherapy in Locally Advanced Non???Small-Cell Lung Cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique???Groupe Fran??ais de Pneumo-Canc??rologie NPC 95-01 Study, Journal of Clinical Oncology, vol.23, issue.25, pp.5910-5917, 2005.
DOI : 10.1200/JCO.2005.03.070

J. Welsh, S. Settle, A. Amini, L. Xiao, A. Suzuki et al., Failure patterns in patients with esophageal cancer treated with definitive chemoradiation, Cancer, vol.76, issue.3 suppl 1, pp.2632-2672, 2012.
DOI : 10.1002/cncr.26586

J. Bradley, A Review of Radiation Dose Escalation Trials for Non-Small Cell Lung Cancer Within the Radiation Therapy Oncology Group, Seminars in Oncology, vol.32, pp.111-113, 2005.
DOI : 10.1053/j.seminoncol.2005.03.020

A. Klopp, J. Chang, S. Tucker, E. Sulman, P. Balter et al., Intrathoracic Patterns of Failure for Non???Small-Cell Lung Cancer??With Positron-Emission Tomography/Computed Tomography???Defined Target Delineation, International Journal of Radiation Oncology*Biology*Physics, vol.69, issue.5, pp.1409-1425, 2007.
DOI : 10.1016/j.ijrobp.2007.05.085

H. Aerts, A. Van-baardwijk, S. Petit, C. Offermann, J. Loon et al., Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy 18Fluorodeoxyglucose-PET-CT scan, Radiotherapy and Oncology, vol.91, issue.3, pp.386-92, 2009.
DOI : 10.1016/j.radonc.2009.03.006

H. Aerts, J. Bussink, W. Oyen, W. Van-elmpt, A. Folgering et al., Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: A prospective validation, Lung Cancer, vol.75, issue.1, pp.73-79, 2012.
DOI : 10.1016/j.lungcan.2011.06.003

J. Van-den-bogaard, M. Janssen, G. Janssens, J. Buijsen, B. Reniers et al., Residual metabolic tumor activity after chemo-radiotherapy is mainly located in initially high FDG uptake areas in rectal cancer, Radiotherapy and Oncology, vol.99, issue.2, pp.137-178, 2011.
DOI : 10.1016/j.radonc.2011.04.004

N. Shusharina, J. Cho, G. Sharp, and N. Choi, Correlation of 18F-FDG Avid Volumes on Pre???Radiation Therapy and Post???Radiation Therapy FDG PET Scans in??Recurrent Lung Cancer, International Journal of Radiation Oncology*Biology*Physics, vol.89, issue.1, pp.137-181, 2014.
DOI : 10.1016/j.ijrobp.2014.01.047

A. Edet-sanson, B. Dubray, K. Doyeux, A. Back, S. Hapdey et al., Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC), Radiotherapy and Oncology, vol.102, issue.2, pp.251-257, 2012.
DOI : 10.1016/j.radonc.2011.07.023

URL : https://hal.archives-ouvertes.fr/hal-00673355

P. Vera, S. Mezzani-saillard, A. Edet-sanson, J. Ménard, R. Modzelewski et al., FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2), European Journal of Nuclear Medicine and Molecular Imaging, vol.22, issue.2, pp.1057-65, 2014.
DOI : 10.1007/s00259-014-2687-9

S. Thureau, P. Chaumet-riffaud, R. Modzelewski, P. Fernandez, L. Tessonnier et al., Interobserver Agreement of Qualitative Analysis and Tumor Delineation of 18F-Fluoromisonidazole and 3'-Deoxy-3'-18F-Fluorothymidine PET Images in Lung Cancer, Journal of Nuclear Medicine, vol.54, issue.9, pp.1543-50, 2013.
DOI : 10.2967/jnumed.112.118083

H. Aerts, G. Bosmans, A. Van-baardwijk, A. Dekker, M. Oellers et al., Stability of 18F-Deoxyglucose Uptake Locations Within Tumor During Radiotherapy for NSCLC: A Prospective Study, International Journal of Radiation Oncology*Biology*Physics, vol.71, issue.5, pp.1402-1409, 2008.
DOI : 10.1016/j.ijrobp.2007.11.049

W. Van-elmpt, D. Ruysscher, D. Van-der-salm, A. Lakeman, A. Van-der-stoep et al., The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer, Radiotherapy and Oncology, vol.104, issue.1, pp.67-71, 2012.
DOI : 10.1016/j.radonc.2012.03.005

W. Lu, S. Tan, G. Kim, S. Feigenberg, H. Zhang et al., Pre-Chemoradiation Therapy FDG PET/CT Cannot Identify Residual Metabolically Active Areas in Patients With Locally Advanced Esophageal Cancer, International Journal of Radiation Oncology*Biology*Physics, vol.84, issue.3, p.312, 2012.
DOI : 10.1016/j.ijrobp.2012.07.815

V. Mazeau-woynar, N. Cerf, G. Dixsaut, C. Canet, C. Prot et al., Survie attendue des patients atteints de cancers en france : état des lieux, Institut National du Cancer, p.18, 2010.

A. Klopp, J. Chang, S. Tucker, E. Sulman, P. Balter et al., Intrathoracic Patterns of Failure for Non???Small-Cell Lung Cancer??With Positron-Emission Tomography/Computed Tomography???Defined Target Delineation, International Journal of Radiation Oncology*Biology*Physics, vol.69, issue.5, pp.1409-1425, 2007.
DOI : 10.1016/j.ijrobp.2007.05.085

A. Abramyuk, S. Tokalov, K. Zöphel, A. Koch, K. Szluha-lazanyi et al., Is pre-therapeutical FDG-PET/CT capable to detect high risk tumor subvolumes responsible for local failure in non-small cell lung cancer?, Radiotherapy and Oncology, vol.91, issue.3, pp.399-404, 2009.
DOI : 10.1016/j.radonc.2009.01.003

H. Aerts, A. Van-baardwijk, S. Petit, and C. Offermann, Identification of radioresistance: Validation of location residual metabolic-active areas. Molecular imaging of biologic characteristics and drug uptake, 2010.

H. J. Aerts, J. Bussink, W. J. Oyen, W. Van-elmpt, A. M. Folgering et al., Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: A prospective validation, Lung Cancer, vol.75, issue.1, pp.73-76, 2012.
DOI : 10.1016/j.lungcan.2011.06.003

D. Møller, A. Khalil, M. Knap, L. Muren, and L. Hoffmann, A planning study of radiotherapy dose escalation of PET-active tumour volumes in non-small cell lung cancer patients, Acta Oncologica, vol.70, issue.6, pp.883-891, 2011.
DOI : 10.3109/0284186X.2010.504735

W. Van-elmpt, D. Ruysscher, D. Van-der-salm, A. Lakeman, A. Van-der-stoep et al., The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer, Radiotherapy and Oncology, vol.104, issue.1, pp.67-71, 2012.
DOI : 10.1016/j.radonc.2012.03.005

A. Edet-sanson, B. Dubray, K. Doyeux, A. Back, S. Hapdey et al., Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC), Radiotherapy and Oncology, vol.102, issue.2, pp.251-257, 2012.
DOI : 10.1016/j.radonc.2011.07.023

URL : https://hal.archives-ouvertes.fr/hal-00673355

P. Vera, S. Mezzani-saillard, A. Edet-sanson, J. Ménard, R. Modzelewski et al., FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2), European Journal of Nuclear Medicine and Molecular Imaging, vol.22, issue.2, 2014.
DOI : 10.1007/s00259-014-2687-9

S. Thureau, P. Chaumet-riffaud, R. Modzelewski, P. Fernandez, L. Tessonnier et al., Interobserver Agreement of Qualitative Analysis and Tumor Delineation of 18F-Fluoromisonidazole and 3'-Deoxy-3'-18F-Fluorothymidine PET Images in Lung Cancer, Journal of Nuclear Medicine, vol.54, issue.9, pp.1543-50, 2013.
DOI : 10.2967/jnumed.112.118083

S. Ourselin, A. Roche, S. Prima, S. Ayache, and N. , Block Matching: A??General??Framework??to??Improve Robustness of??Rigid??Registration of Medical Images, MICCAI LNCS 1935, pp.557-566, 2000.
DOI : 10.1007/978-3-540-40899-4_57

URL : https://hal.archives-ouvertes.fr/inria-00615860

V. Paidpally, G. Mercier, B. Shah, S. Senthamizhchelvan, and R. Subramaniam, Interreader Agreement and Variability of FDG PET Volumetric Parameters in Human Solid Tumors, American Journal of Roentgenology, vol.202, issue.2, pp.406-418, 2014.
DOI : 10.2214/AJR.13.10841

Y. Erdi, O. Mawlawi, S. Larson, M. Imbriaco, H. Yeung et al., Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding, Cancer, vol.34, issue.S12, pp.2505-2514, 1997.
DOI : 10.1002/(SICI)1097-0142(19971215)80:12+<2505::AID-CNCR24>3.0.CO;2-F

M. Mehta and M. R. , Are More Aggressive Therapies Able to Improve Treatment of Locally Advanced Non-Small Cell Lung Cancer: Combined Modality Treatment?, Seminars in Oncology, vol.32, pp.25-34, 2005.
DOI : 10.1053/j.seminoncol.2005.03.007

E. Velazquez, H. Aerts, C. Oberije, D. Ruysscher, D. Lambin et al., Prediction of residual metabolic activity after treatment in NSCLC patients, Acta Oncologica, vol.29, issue.2, pp.1033-1042, 2010.
DOI : 10.1016/S0167-8140(99)00087-0

M. Machtay, F. Duan, B. Siegel, B. Snyder, J. Gorelick et al., F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Locally Advanced Non???Small-Cell Lung Cancer Undergoing Definitive Chemoradiation Therapy: Results of the ACRIN 6668/RTOG 0235 Trial, Journal of Clinical Oncology, vol.31, issue.30, pp.3823-3853, 2013.
DOI : 10.1200/JCO.2012.47.5947

H. Aerts, G. Bosmans, A. Van-baardwijk, A. Dekker, M. Oellers et al., Stability of 18F-Deoxyglucose Uptake Locations Within Tumor During Radiotherapy for NSCLC: A Prospective Study, International Journal of Radiation Oncology*Biology*Physics, vol.71, issue.5, pp.1402-1409, 2008.
DOI : 10.1016/j.ijrobp.2007.11.049

J. Bradley, J. Moughan, and M. Graham, A Phase I/II Radiation Dose Escalation Study With Concurrent Chemotherapy for Patients With Inoperable Stages I to III Non-Small-Cell Lung Cancer: Phase I Results of RTOG 0117, International Journal of Radiation Oncology*Biology*Physics, vol.77, issue.2, pp.367-372, 2010.
DOI : 10.1016/j.ijrobp.2009.04.029

J. Bradley, R. Paulus, R. Komaki, G. Masters, K. Forster et al., A Randomized Phase III Comparison of Standard-Dose (60 Gy) Versus High-dose (74 Gy) Conformal Chemoradiotherapy +/-Cetuximab for Stage IIIA/IIIB Non-Small Cell Lung Cancer: Preliminary Findings on Radiation Dose in RTOG 0617 [late-breaking abstract], ASTRO, p.201, 2011.

J. Bradley, R. Paulus, R. Komaki, G. Masters, K. Forster et al., A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617, J Clin Oncol, issue.15, p.317501, 2013.

R. Wijsman, J. Kaanders, W. Oyen, and J. Bussink, Hypoxia and tumor metabolism in radiation oncology: targets visualized by positron emission tomography, Q J Nucl Med Mol Imaging, vol.57, issue.3, pp.244-56, 2013.

K. Kaira, M. Serizawa, Y. Koh, T. Takahashi, A. Yamaguchi et al., Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer, Lung Cancer, vol.83, issue.2, pp.197-204, 2014.
DOI : 10.1016/j.lungcan.2013.11.025

M. Lopez-lazaro, The Warburg Effect: Why and How Do Cancer Cells Activate Glycolysis in the Presence of Oxygen? Anti-Cancer Agents in Medicinal Chemistry-Anti-Cancer Agents), pp.305-317, 2008.

M. Heiden, L. Cantley, and C. Thompson, Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation, Science, vol.324, issue.5930, pp.1029-1062, 2009.
DOI : 10.1126/science.1160809

R. Gatenby and R. Gillies, Why do cancers have high aerobic glycolysis? Nat Rev Cancer, pp.891-900, 2004.

T. Seagroves, H. Ryan, H. Lu, B. Wouters, M. Knapp et al., Transcription Factor HIF-1 Is a Necessary Mediator of the Pasteur Effect in Mammalian Cells, Molecular and Cellular Biology, vol.21, issue.10, pp.3436-3480, 2001.
DOI : 10.1128/MCB.21.10.3436-3444.2001

G. Mees, R. Dierckx, C. Vangestel, D. Laukens, N. Van-damme et al., Pharmacologic activation of tumor hypoxia: a means to increase tumor 2-deoxy-2-[18F]fluoro-D-glucose uptake? Mol Imaging, pp.49-58, 2013.

A. Van-baardwijk, C. Dooms, R. Van-suylen, E. Verbeken, M. Hochstenbag et al., The maximum uptake of 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1?? and GLUT-1 in non-small cell lung cancer, European Journal of Cancer, vol.43, issue.9, pp.1392-1400, 2007.
DOI : 10.1016/j.ejca.2007.03.027

J. Fowler, W. Tome, J. Fenwick, and M. Mehta, A challenge to traditional radiation oncology, International Journal of Radiation Oncology*Biology*Physics, vol.60, issue.4, pp.1241-56, 2004.
DOI : 10.1016/j.ijrobp.2004.07.691

A. Pennathur, M. Gibson, B. Jobe, and J. Luketich, Oesophageal carcinoma, The Lancet, vol.381, issue.9864, pp.400-412, 2013.
DOI : 10.1016/S0140-6736(12)60643-6

C. Pöttgen and M. Stuschke, Radiotherapy versus surgery within multimodality protocols for esophageal cancer ??? A meta-analysis of the randomized trials, Cancer Treatment Reviews, vol.38, issue.6, pp.599-604, 2012.
DOI : 10.1016/j.ctrv.2011.10.005

L. Bedenne, P. Michel, O. Bouché, C. Milan, C. Mariette et al., Chemoradiation Followed by Surgery Compared With Chemoradiation Alone in Squamous Cancer of the Esophagus: FFCD 9102, Journal of Clinical Oncology, vol.25, issue.10, pp.1160-1168, 2007.
DOI : 10.1200/JCO.2005.04.7118

URL : https://hal.archives-ouvertes.fr/hal-00363743

A. Herskovic, W. Russell, M. Liptay, M. Fidler, and M. Sarraf, Esophageal carcinoma advances in treatment results for locally advanced disease: review, Annals of Oncology, vol.23, issue.5, pp.1095-103, 2012.
DOI : 10.1093/annonc/mdr433

B. Minsky, T. Pajak, R. Ginsberg, T. Pisansky, J. Martenson et al., INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation Therapy, Journal of Clinical Oncology, vol.20, issue.5, pp.1167-74, 2002.
DOI : 10.1200/JCO.2002.20.5.1167

P. Michel, A. Adenis, F. Fiore, E. Boucher, M. Galais et al., Induction cisplatin???irinotecan followed by concurrent cisplatin???irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial, British Journal of Cancer, vol.88, issue.6, pp.705-714, 2006.
DOI : 10.1038/sj.bjc.6690233

J. Welsh, S. Settle, A. Amini, L. Xiao, A. Suzuki et al., Failure patterns in patients with esophageal cancer treated with definitive chemoradiation, Cancer, vol.76, issue.3 suppl 1, pp.2632-2672, 2012.
DOI : 10.1002/cncr.26586

J. Welsh, M. Palmer, J. Ajani, Z. Liao, S. Swisher et al., Esophageal Cancer Dose Escalation Using a Simultaneous Integrated Boost Technique, International Journal of Radiation Oncology*Biology*Physics, vol.82, issue.1, pp.468-74, 2012.
DOI : 10.1016/j.ijrobp.2010.10.023

A. Chandra, T. Guerrero, H. Liu, S. Tucker, Z. Liao et al., Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer, Radiotherapy and Oncology, vol.77, issue.3, pp.247-53, 2005.
DOI : 10.1016/j.radonc.2005.10.017

W. Fu, L. Wang, Z. Zhou, J. Dai, Y. Hu et al., Comparison of conformal and intensity-modulated techniques for simultaneous integrated boost radiotherapy of upper esophageal carcinoma, World J. Gastroenterol. WJG, vol.10, pp.1098-102, 2004.

T. Kole, O. Aghayere, J. Kwah, E. Yorke, and K. Goodman, Comparison of Heart and Coronary Artery Doses Associated With Intensity-Modulated Radiotherapy Versus Three-Dimensional Conformal Radiotherapy for Distal Esophageal Cancer, International Journal of Radiation Oncology*Biology*Physics, vol.83, issue.5, pp.1580-1586, 2012.
DOI : 10.1016/j.ijrobp.2011.10.053

S. Martin, J. Chen, R. Dar, A. Yartsev, and S. , Dosimetric comparison of helical tomotherapy, RapidArc, and a novel IMRT & Arc technique for esophageal carcinoma, Radiotherapy and Oncology, vol.101, issue.3, pp.431-438, 2011.
DOI : 10.1016/j.radonc.2011.08.030

V. Wu, J. Sham, and D. Kwong, Inverse planning in three-dimensional conformal and intensity-modulated radiotherapy of mid-thoracic oesophageal cancer, The British Journal of Radiology, vol.77, issue.919, pp.568-72, 2004.
DOI : 10.1259/bjr/19972578

J. Welsh, D. Gomez, M. Palmer, B. Riley, A. Mayankkumar et al., Intensity-Modulated Proton Therapy Further Reduces Normal Tissue Exposure During Definitive Therapy for Locally Advanced Distal Esophageal Tumors: A Dosimetric Study, International Journal of Radiation Oncology*Biology*Physics, vol.81, issue.5, pp.1336-1378, 2011.
DOI : 10.1016/j.ijrobp.2010.07.2001

T. Barber, C. Duong, T. Leong, M. Bressel, E. Drummond et al., 18F-FDG PET/CT Has a High Impact on Patient Management and Provides Powerful Prognostic Stratification in the Primary Staging of Esophageal Cancer: A Prospective Study with Mature Survival Data, Journal of Nuclear Medicine, vol.53, issue.6, pp.864-71, 2012.
DOI : 10.2967/jnumed.111.101568

H. Van-westreenen, M. Westerterp, P. Bossuyt, J. Pruim, G. Sloof et al., F-Fluorodeoxyglucose Positron Emission Tomography in Esophageal Cancer, Journal of Clinical Oncology, vol.22, issue.18
DOI : 10.1200/JCO.2004.01.083

M. Lambrecht and K. Haustermans, Clinical evidence on PET-CT for radiation therapy planning in gastro-intestinal tumors, Radiotherapy and Oncology, vol.96, issue.3, pp.339-385, 2010.
DOI : 10.1016/j.radonc.2010.07.019

W. Yu, X. Fu, Y. Zhang, J. Xiang, L. Shen et al., GTV spatial conformity between different delineation methods by 18FDG PET/CT and pathology in esophageal cancer, Radiotherapy and Oncology, vol.93, issue.3, pp.441-447, 2009.
DOI : 10.1016/j.radonc.2009.07.003

H. Aerts, A. Van-baardwijk, S. Petit, C. Offermann, J. Loon et al., Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy 18Fluorodeoxyglucose-PET-CT scan, Radiotherapy and Oncology, vol.91, issue.3, pp.386-92, 2009.
DOI : 10.1016/j.radonc.2009.03.006

H. Aerts, J. Bussink, W. Oyen, W. Van-elmpt, A. Folgering et al., Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: A prospective validation, Lung Cancer, vol.75, issue.1, pp.73-79, 2012.
DOI : 10.1016/j.lungcan.2011.06.003

J. Van-den-bogaard, M. Janssen, G. Janssens, J. Buijsen, B. Reniers et al., Residual metabolic tumor activity after chemo-radiotherapy is mainly located in initially high FDG uptake areas in rectal cancer, Radiotherapy and Oncology, vol.99, issue.2, pp.137-178, 2011.
DOI : 10.1016/j.radonc.2011.04.004

A. Herskovic, K. Martz, M. Sarraf, L. Leichman, J. Brindle et al., Combined Chemotherapy and Radiotherapy Compared with Radiotherapy Alone in Patients with Cancer of the Esophagus, New England Journal of Medicine, vol.326, issue.24, pp.1593-1601, 1992.
DOI : 10.1056/NEJM199206113262403

V. Paidpally, G. Mercier, B. Shah, S. Senthamizhchelvan, and R. Subramaniam, Interreader Agreement and Variability of FDG PET Volumetric Parameters in Human Solid Tumors, American Journal of Roentgenology, vol.202, issue.2, pp.406-418, 2014.
DOI : 10.2214/AJR.13.10841

D. Fiore, F. Blondin, V. Hitzel, A. Edet-sanson, A. Benyoucef et al., 18F-fluorodeoxyglucose positron emission tomography after definitive chemoradiotherapy in patients with oesophageal carcinoma, Digestive and Liver Disease, vol.44, issue.10, pp.875-884, 2012.
DOI : 10.1016/j.dld.2012.04.017

URL : https://hal.archives-ouvertes.fr/hal-00942163

O. Palie, P. Michel, J. Ménard, C. Rousseau, E. Rio et al., The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3), European Journal of Nuclear Medicine and Molecular Imaging, vol.38, issue.7, pp.1345-55, 2013.
DOI : 10.1007/s00259-013-2450-7

C. Lemarignier, D. Fiore, F. Marre, C. Hapdey, S. Modzelewski et al., Pretreatment metabolic tumour volume is predictive of disease-free survival and overall survival in patients with oesophageal squamous cell carcinoma, European Journal of Nuclear Medicine and Molecular Imaging, vol.40, issue.11, p.2014, 2014.
DOI : 10.1007/s00259-014-2839-y

URL : https://hal.archives-ouvertes.fr/hal-01120600

S. Ourselin, A. Roche, S. Prima, and N. Ayache, Block Matching: A??General??Framework??to??Improve Robustness of??Rigid??Registration of Medical Images, Med. Image Comput. Comput.-Assist
DOI : 10.1007/978-3-540-40899-4_57

URL : https://hal.archives-ouvertes.fr/inria-00615860

. ?. Interv and . Miccai, Available from, pp.557-66978, 1007.

S. Thureau, P. Chaumet-riffaud, R. Modzelewski, P. Fernandez, L. Tessonnier et al., Interobserver Agreement of Qualitative Analysis and Tumor Delineation of 18F-Fluoromisonidazole and 3'-Deoxy-3'-18F-Fluorothymidine PET Images in Lung Cancer, Journal of Nuclear Medicine, vol.54, issue.9, pp.1543-50, 2013.
DOI : 10.2967/jnumed.112.118083

W. Lu, S. Tan, G. Kim, S. Feigenberg, H. Zhang et al., Pre-Chemoradiation Therapy FDG PET/CT Cannot Identify Residual Metabolically Active Areas in Patients With Locally Advanced Esophageal Cancer, International Journal of Radiation Oncology*Biology*Physics, vol.84, issue.3, p.312, 2012.
DOI : 10.1016/j.ijrobp.2012.07.815

R. Wijsman, J. Kaanders, W. Oyen, and J. Bussink, Hypoxia and tumor metabolism in radiation oncology: targets visualized by positron emission tomography, Q. J. Nucl. Med. Mol. Imaging Off. Publ. Ital. Assoc. Nucl. Med. AIMN Int. Assoc. Radiopharmacol. IAR Sect. Soc. Radiopharm. Chem. Biol, vol.57, pp.244-56, 2013.

K. Kaira, M. Serizawa, Y. Koh, T. Takahashi, A. Yamaguchi et al., Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer, Lung Cancer, vol.83, issue.2, pp.197-204, 2014.
DOI : 10.1016/j.lungcan.2013.11.025

M. Lopez-lazaro, The Warburg Effect: Why and How Do Cancer Cells Activate Glycolysis in the Presence of Oxygen?, Anti-Cancer Agents in Medicinal Chemistry, vol.8, issue.3, pp.305-317, 2008.
DOI : 10.2174/187152008783961932

M. Heiden, L. Cantley, and C. Thompson, Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation, Science, vol.324, issue.5930, pp.1029-1062, 2009.
DOI : 10.1126/science.1160809

R. Gatenby and R. Gillies, Why do cancers have high aerobic glycolysis?, Nature Reviews Cancer, vol.62, issue.11, pp.891-900, 2004.
DOI : 10.1038/nrc1478

T. Seagroves, H. Ryan, H. Lu, B. Wouters, M. Knapp et al., Transcription Factor HIF-1 Is a Necessary Mediator of the Pasteur Effect in Mammalian Cells, Molecular and Cellular Biology, vol.21, issue.10, pp.3436-3480, 2001.
DOI : 10.1128/MCB.21.10.3436-3444.2001

G. Mees, R. Dierckx, C. Vangestel, D. Laukens, N. Van-damme et al., Pharmacologic activation of tumor hypoxia: a means to increase tumor 2-deoxy-2-[18F]fluoro-D-glucose uptake?, Mol. Imaging, vol.12, pp.49-58, 2013.

A. Van-baardwijk, C. Dooms, R. Van-suylen, E. Verbeken, M. Hochstenbag et al., The maximum uptake of 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1?? and GLUT-1 in non-small cell lung cancer, European Journal of Cancer, vol.43, issue.9, pp.1392-1400, 2007.
DOI : 10.1016/j.ejca.2007.03.027

M. Hatt, D. Visvikis, O. Pradier, and C. Rest, Baseline 18F-FDG PET image-derived parameters for therapy response prediction in oesophageal cancer, European Journal of Nuclear Medicine and Molecular Imaging, vol.17, issue.1, pp.1595-606, 2011.
DOI : 10.1007/s00259-011-1834-9

URL : https://hal.archives-ouvertes.fr/inserm-00595534

S. Hyun, J. Choi, Y. Shim, K. Kim, S. Lee et al., Prognostic Value of Metabolic Tumor Volume Measured by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Esophageal Carcinoma, Annals of Surgical Oncology, vol.34, issue.1, pp.115-137, 2010.
DOI : 10.1245/s10434-009-0719-7

L. Shukovsky and G. Fletcher, Time-Dose and Tumor Volume Relationships in the Irradiation of Squamous Cell Carcinoma of the Tonsillar Fossa, Radiology, vol.107, issue.3, pp.621-627, 1973.
DOI : 10.1148/107.3.621

P. Vera, B. Dubray, O. Palie, I. Buvat, S. Hapdey et al., Monitoring tumour response during chemo-radiotherapy: a parametric method using FDG-PET/CT images in patients with oesophageal cancer, EJNMMI Research, vol.4, issue.1, p.12, 2014.
DOI : 10.1186/2191-219X-4-12

URL : https://hal.archives-ouvertes.fr/hal-01141152

H. Necib, C. Garcia, A. Wagner, B. Vanderlinden, P. Emonts et al., Detection and Characterization of Tumor Changes in 18F-FDG PET Patient Monitoring Using Parametric Imaging, Journal of Nuclear Medicine, vol.52, issue.3, pp.354-61, 2011.
DOI : 10.2967/jnumed.110.080150

M. Hawkins, A. Aitken, V. Hansen, H. Mcnair, and D. Tait, Cone beam CT verification for oesophageal cancer ??? impact of volume selected for image registration, Acta Oncologica, vol.65, issue.2, pp.1183-90, 2011.
DOI : 10.1016/j.ijrobp.2006.03.064

C. Menzel, N. Döbert, O. Rieker, W. Kneist, S. Mose et al., 18F-Deoxyglucose PET for the staging of oesophageal cancer: influence of histopathological subtype and tumour grading], Nukl. Nucl. Med, vol.42, pp.90-93, 2003.

N. Au-pr-jean and . Dacher, pour l'accueil sympathique dans le service de radiologie et pour m'avoir formé en imagerie cardiaque

F. Au-dr and . Paycha, pour tes connaissances, ta pédagogie, notre case report sur le lymphome osseux et pour m'avoir formé en scintigraphie osseuse

L. Au-dr, Vercellino pour ta gentillesse et nos meetings en province. Pour m'avoir formé en TEP et transmis l'approche « Sherlock Holmes », et donc passionnante

J. Au-dr and . Ohnona, pour nos vacations de TEP formatrices et agréables. Nos échanges m'ont beaucoup apporté

L. Au-dr and . Mabille, pour m'avoir formé en TEP et fait partager ton expérience

E. Au-dr and . Blanc, best-chief-ever, pour m'avoir formé en TEP lors de nos vacations-debriefs si cools, le case report Priapisme-FDG, ton humour et ton

J. Au-dr and . Filmont, JEF, véritable guide initiatique, pour tous les conseils d'orientation, l'écoute, le temps et la considération que tu m'as accordés, notamment au début de mon internat. Pour nos posters sur la Choline, nos déjeuners, nos diners, nos pintes de blonde, notamment celle sous 18 F-Choline